AquaBounty Technologies, Inc, a biotechnology company, develops and markets products to enhance productivity in aquaculture. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. The company was formerly known as Aqua Bounty Farms, Inc and changed its name to AquaBounty Technologies, Inc in June 2004. AquaBounty Technologies, Inc was founded in 1991 and is headquartered in Maynard, Massachusetts.
Read More…
Industry, Sector and Symbol
Industry Fishing, hunting & trapping
Sub-IndustryN/A
SectorMedical
Phone978-648-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date11/1/2019 (Estimated)
OptionableNot Optionable
Aquabounty Technologies (NASDAQ:AQB) Frequently Asked Questions
What is Aquabounty Technologies' stock symbol?
Aquabounty Technologies trades on the NASDAQ under the ticker symbol "AQB."
How were Aquabounty Technologies' earnings last quarter?
Aquabounty Technologies Inc (NASDAQ:AQB) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The company earned $0.04 million during the quarter, compared to analyst estimates of $0.01 million. Aquabounty Technologies had a negative net margin of 7,510.69% and a negative return on equity of 46.82%. View Aquabounty Technologies' Earnings History.
When is Aquabounty Technologies' next earnings date?
What price target have analysts set for AQB?
2 brokers have issued 12-month price targets for Aquabounty Technologies' stock. Their predictions range from $4.00 to $5.00. On average, they expect Aquabounty Technologies' share price to reach $4.50 in the next year. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Price Targets for Aquabounty Technologies.
What is the consensus analysts' recommendation for Aquabounty Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquabounty Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquabounty Technologies.
What are Wall Street analysts saying about Aquabounty Technologies stock?
Here are some recent quotes from research analysts about Aquabounty Technologies stock:
- 1. According to Zacks Investment Research, "AquaBounty Technologies, Inc. is a biotechnology company. It focused on enhancing productivity in aquaculture. The company operates primarily in Maynard, Massachusetts and Fortune, Prince Edward Island. AquaBounty Technologies, Inc. is based in Maynard, United States. " (8/26/2019)
- 2. National Securities analysts commented, " Second Quarter Results. An operating loss of $4.0 million fell below our estimated loss of $2.8 million, driven largely by sequential increases in G&A from $2.0 million in the first quarter to $3.1 million in the second quarter. We believe some of the increases were one time in nature, although we believe our prior OpEx estimates in advance of commercialization were too light.
Production Schedule On Track. With AquAdvantage Salmon (AAS) in the Indiana and Rollo Bay grow out facilities, we continue to expect initial harvests by the end of 2020. A one-time harvest of conventional salmon is also expected in the third quarter of 2020. We look for a regular introduction of AAS into the grow out phase which should enable year-round harvest.
What Is Next? With production now underway in both facilities, we believe management is focused on securing buyers for the initial harvest and making preliminary estimates on future expansion. The commercial team is being developed, highlighted by the introduction of CCO David Melbourne Jr in the quarter. We believe expansion plans will be formally announced as commercial revenues are realized and will initially be an expansion of the current Indiana facility.
Initial AAS Buyer The Next Major Catalyst. We believe a formal announcement of the first buyers of AAS will represent a significant catalyst for the stock. With the first harvest of AAS anticipated in the third quarter of 2020, we expect buyers to commit around the Spring of 2020. We expect investors on the sideline are awaiting this announcement, and thus believe as buyers are secured and visibility of revenue is enhanced that shares will make a meaningful and sustainable movement upward." (8/7/2019)
Has Aquabounty Technologies been receiving favorable news coverage?
Media stories about AQB stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aquabounty Technologies earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aquabounty Technologies.
Are investors shorting Aquabounty Technologies?
Aquabounty Technologies saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 298,600 shares, a decrease of 18.2% from the August 30th total of 364,900 shares. Based on an average daily volume of 108,900 shares, the short-interest ratio is currently 2.7 days. Approximately 2.6% of the shares of the stock are short sold. View Aquabounty Technologies' Current Options Chain.
Who are some of Aquabounty Technologies' key competitors?
Some companies that are related to Aquabounty Technologies include Athersys (ATHX), SeaSpine (SPNE), Poxel (PXXLF), Kamada (KMDA), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), LifeVantage (LFVN), American Renal Associates (ARA), Spero Therapeutics (SPRO), RTI Surgical (RTIX), Chiasma (CHMA), GlycoMimetics (GLYC), Genesis Healthcare (GEN), Evelo Biosciences (EVLO) and Kalvista Pharmaceuticals (KALV).
What other stocks do shareholders of Aquabounty Technologies own?
Who are Aquabounty Technologies' key executives?
Aquabounty Technologies' management team includes the folowing people:
- Mr. David A. Frank, CFO & Treasurer (Age 59)
- Dr. Ronald L. Stotish, Exec. Director & Chief Technology Officer (Age 70)
- Mr. Alejandro Rojas, Chief Operating Officer of Aquabounty Farms (Age 57)
- Ms. Sylvia Wulf, CEO, Pres & Exec. Director (Age 61)
- Mr. Christopher H. Martin, Gen. Counsel & Company Sec. (Age 53)
How do I buy shares of Aquabounty Technologies?
Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aquabounty Technologies' stock price today?
One share of AQB stock can currently be purchased for approximately $2.37.
How big of a company is Aquabounty Technologies?
Aquabounty Technologies has a market capitalization of $51.20 million and generates $90,000.00 in revenue each year. The company earns $-10,380,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Aquabounty Technologies employs 39 workers across the globe.View Additional Information About Aquabounty Technologies.
What is Aquabounty Technologies' official website?
How can I contact Aquabounty Technologies?
Aquabounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected]
MarketBeat Community Rating for Aquabounty Technologies (NASDAQ AQB)
MarketBeat's community ratings are surveys of what our community members think about Aquabounty Technologies and other stocks. Vote "Outperform" if you believe AQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQB will underperform the S&P 500 over the long term. You may vote once every thirty days.
